Skip to main content

Table 1 Demographic and clinical characteristics of the BMD <70 % of YAM and BMD ≥70 % of YAM groups

From: Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics

 

BMD <70 % of YAM

BMD ≥70 % of YAM

p value

Age

65.0 (58.0–69.0)

58.0 (53.0–66.0)

0.0044*

Proportion female

93.0 %

77.9 %

0.0079*

Disease duration (year)

15.0 (8.0–20.0)

8.0 (4.0–15.0)

0.0004*

BMI

21.4 ± 2.8

23.6 ± 3.3

<0.0001*

Rate of rheumatoid vasculitis

1.8 %

1.6 %

0.67

Proportion taking methylprednisolone

45.6 %

40.3 %

0.52

Dose of methylprednisolone (mg)

2.0 (1.0–3.5)

3.3 (2.0–6.0)

0.65

CRP (mg/dL)

0.09 (0.03–0.31)

0.08 (0.03–0.37)

0.89

DAS28-CRP

2.63 (1.88–3.38)

2.50 (1.70–3.30)

0.49

CDAI

6.70 (2.90–14.90)

5.80 (2.60–12.95)

0.54

SDAI

6.95 (3.05–14.10)

6.30 (2.74–12.94)

0.58

MHAQ score

9.00 (1.00–14.00)

4.00 (0.00–8.00)

0.002*

History of proximal femoral fracture

2/57

0/129

0.087

History of thoracic or lumbar vertebral fracture

17/57

9/129

<0.001*

Duration of biologics therapy

4.2 ± 2.6

3.6 ± 2.3

0.166

  1. BMD bone mineral density, YAM young adult mean, BMI body mass index, CRP serum C-reactive protein concentration, DAS28-CRP Disease Activity Score-28-CRP, SDAI Simplified Disease Activity Index, CDAI Clinical Disease Activity Index, MHAQ Modified Health Assessment Questionnaire